Exome sequencing identifies a new Alzheimer’s risk gene—phospholipase D3.
Researchers at BACE meeting explore how trafficking and degradation of the protease relate to amyloid pathology in AD.
Are New Cognitive Tests Ready For Preclinical Trials? Do Tau Tracers Track Cognitive Decline in Disease? Growth Factor Therapy: Safe in Phase 1, Awaiting Efficacy Data Clinical Trials on Alzheimer’s Disease 2013 ...
Older people improved memory and attention after playing a challenging video game, supporting the idea that multitasking could have benefits for cognition.
Leaders protest recent decision to deny Medicare beneficiaries coverage of amyloid scans.
Update on compounds in Phase 2 and 3 trials from the Alzheimer's Association International Conference
Speakers at Alzheimer’s conference reviewed planned Phase 1 and prevention trials and preclinical studies.
Studies reported at AAIC demonstrate that biomarkers help predict who will develop cognitive impairment and dementia.
Researchers are increasingly branching out from their old focus on Aβ and tau to understand how these proteins intersect with physiological processes and new genetic regulatory mechanisms in the aging brain.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
Researchers at AAIC 2013 report that an individual’s subjective sense of worsening memory could be an important predictor of cognitive impairment and dementia.
A small panel of fluid biomarkers could predict a slow or fast disease course in amyotrophic lateral sclerosis.
Much like people with Alzheimer's, mice modelling the disease experience seizures. New research suggests that APP, and not Aβ, makes their neurons hyperexcitable.
New imaging data suggests degeneration of the fornix could help identify seniors on the verge of cognitive decline.
A new grant opportunity will fund projects aimed at understanding the similarities and differences between biomarkers of Alzheimer’s and Parkinson’s diseases.